Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non Operating Income (2021 - 2025)

Historic Non Operating Income for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $1.6 million.

  • Amylyx Pharmaceuticals' Non Operating Income fell 4450.46% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year decrease of 4937.26%. This contributed to the annual value of $12.6 million for FY2024, which is 1871.57% down from last year.
  • Amylyx Pharmaceuticals' Non Operating Income amounted to $1.6 million in Q3 2025, which was down 4450.46% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Non Operating Income peaked at $4.5 million during Q4 2023, and registered a low of -$3.3 million during Q2 2021.
  • Over the past 5 years, Amylyx Pharmaceuticals' median Non Operating Income value was $1.9 million (recorded in 2025), while the average stood at $1.7 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Non Operating Income skyrocketed by 861034.48% in 2022 and then plummeted by 6056.89% in 2025.
  • Amylyx Pharmaceuticals' Non Operating Income (Quarter) stood at -$29000.0 in 2021, then soared by 8610.34% to $2.5 million in 2022, then skyrocketed by 84.04% to $4.5 million in 2023, then tumbled by 45.55% to $2.5 million in 2024, then crashed by 33.64% to $1.6 million in 2025.
  • Its Non Operating Income stands at $1.6 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.9 million for Q1 2025.